Not only would Mylan have to wait longer to launch its generic, the longer wait would mean that other generic drug companies would have time to jump the regulatory, legal, and manufacturing hurdles needed to market their own copies.

FORBES: Judge Tosses Mylan Lipitor Suit, Misses The Point